Development of a nappy for the detection of Cytomegalovirus (CMV) in the urine of neonates
Development of a nappy for the detection of Cytomegalovirus (CMV) in the urine of neonates
批准号:
2262757
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --
中文摘要
先天性巨细胞病毒(CMV)感染发生在病毒从母亲向胎儿宫内传播之后。在英国,据估计,每200个婴儿中就有1-4个出生时患有先天性巨细胞病毒,这是导致非遗传性感觉神经性听力损失的最常见原因。每十个患有先天性巨细胞病毒的新生儿中就有一个在出生时会有症状,包括:肝脾肿大、血小板减少、心脏缺陷和颅内钙化。其余的新生儿将没有症状,但其中10%将发展为长期后遗症,其中最常见的是感觉神经性听力损失。在英国,目前的护理标准是考虑在出生后第一个月内治疗患有先天性巨细胞病毒和神经症状(包括听力损失)的新生儿。因此,为了不错过治疗之窗,及时诊断至关重要。由于新生儿通常在出生后不久出院,快速检测将使感染在出院前很容易被识别,从而使医院能够进行进一步的调查。目前巨细胞病毒的检测使用聚合酶链式反应(PCR)来分析有症状的新生儿的体液,这可能需要1-3天,90%(无症状)感染的新生儿被遗漏。如果能开发出一种廉价且简单易用的检测方法,它将彻底改变我们检测先天性巨细胞病毒感染的方式,使每个新生儿都能接受筛查。随着治疗无症状新生儿和婴儿的证据越来越多,巨细胞病毒可能会被加入新生儿筛查计划,但目前的诊断方法可能成本过高。
英文摘要
Congenital cytomegalovirus (CMV) infection occurs following in-utero transmission of virus from mother to foetus. In the UK it is estimated that 1-4 babies in every 200 will be born with congenital CMV, which is the most common cause of non-genetic sensory neural hearing loss. One in ten neonates with congenital CMV will have symptoms at birth including: hepatosplemomegally, thrombocytopaenia, heart defects and intracranial calcification. The remainder of neonates will be asymptomatic but of these, 10% will develop long-term sequelae, the most common of which is sensory neural hearing loss. In the UK, the current standard of care is to consider treatment of neonates with congenital CMV and neurological symptoms (which includes hearing loss) within the first month of life. Prompt diagnosis is therefore essential for the window of treatment not to be missed. As neonates are typically discharged soon after birth, a rapid test would enable infection to be easily identified before discharge, enabling further investigations to be carried out in hospital.Current tests for CMV use polymerase chain reaction (PCR) to analyse bodily fluids of symptomatic neonates, which can take 1-3 days and misses 90% of (asymptomatic) infected newborns. If a cheap and simple to use assay can be developed, it will revolutionise how we detect congenital CMV infections, allowing every neonate to be screened. As more evidence accumulates for the treatment of asymptomatic neonates and infants it is possible that CMV may be added to the newborn screening programme but the current methods of diagnosis may be cost-prohibitive.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
海外基金